Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression - free survival (PFS) of the phase 3 PHILA trial.
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Impactful Shortlisted Abstracts/Publications in HER2+ve Breast Cancer
Chairpersons :
Dr. Bhawna Sirohi, Dr. Chetan Deshmukh
Speaker :
Dr. M. V. Chandrakanth